{‘She possesses no qualifications’: the US healthcare field braces for Høeg's tenure at the FDA.

As the United States continues making sweeping adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by questioning COVID-19 shots in the global health crisis and has zeroed in on potential deaths after COVID-19 immunization in her brief position at the FDA.

Scheduled Overhauls to Childhood Immunization Program

Agency leaders had intended to reveal major changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with many the global community with no evidence for public health gain. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Dr. Høeg is listed to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US so as to align more similar to Denmark's approach, a society with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Expertise

Høeg has little discernible track record in drug development, approval processes or leadership, which has been standard for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for running the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in managing a major agency. She has no expertise in drug approvals.”

Previous heads of the center would “understand legal statutes and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who headed CBER have had.”

This division has an vast portfolio at the FDA, Woodcock stated.

“Everybody just focuses on the new drug program, but the off-patent medication office clears numerous generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a substantial management component to the job, which oversees in excess of 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock concluded.

Response and Controversial Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection signifies more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries stem from incorrect presumptions”.

“This background aligns with the functions of her position,” the representative stated, citing the period Dr. Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a controversial expedited drug-approval program that allegedly troubled her former heads. “By what process are these drugs being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards laxer rules of all drugs, with the exception of vaccines.”

Established Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, past, Howard have noted. She released a study using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership encompassed changing rules for novel immunizations and discontinuing “unnecessary” vaccines, she said post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed excluding teenage boys from obtaining Covid vaccinations.

“She is an all-around dogmatist who starts off with her beliefs and works backwards to accommodate the data in a extremely disingenuous, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|